TOI vs. FLGT, FTRE, EHAB, TALK, AUNA, INNV, CSTL, PSNL, CELC, and LFMD
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Fulgent Genetics (FLGT), Fortrea (FTRE), Enhabit (EHAB), Talkspace (TALK), Auna (AUNA), InnovAge (INNV), Castle Biosciences (CSTL), Personalis (PSNL), Celcuity (CELC), and LifeMD (LFMD). These companies are all part of the "healthcare" industry.
Oncology Institute vs.
Fulgent Genetics (NASDAQ:FLGT) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fulgent Genetics received 240 more outperform votes than Oncology Institute when rated by MarketBeat users. However, 71.43% of users gave Oncology Institute an outperform vote while only 59.76% of users gave Fulgent Genetics an outperform vote.
In the previous week, Fulgent Genetics had 4 more articles in the media than Oncology Institute. MarketBeat recorded 8 mentions for Fulgent Genetics and 4 mentions for Oncology Institute. Fulgent Genetics' average media sentiment score of 0.97 beat Oncology Institute's score of 0.13 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics currently has a consensus price target of $24.00, indicating a potential upside of 16.96%. Oncology Institute has a consensus price target of $7.00, indicating a potential upside of 134.11%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Fulgent Genetics.
Oncology Institute has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute has a net margin of -17.63% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat Oncology Institute's return on equity.
Fulgent Genetics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Oncology Institute has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Summary
Fulgent Genetics beats Oncology Institute on 10 of the 17 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
This page (NASDAQ:TOI) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy TOI Stock Free TOI Stock Alerts